TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.63
+0.62%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.55
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.69
- EPS estimate
- -$0.70
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -5.8%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $7.50
- PT range
- $5.00 – $10
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.70 | -$0.69 | Beat 2.05% | — |
| May 8, 2026 | -$0.65 | -$0.73 | Miss -12.31% | — |
| Mar 31, 2026 | -$0.55 | -$0.78 | Miss -41.82% | — |
| Nov 13, 2025 | -$0.83 | -$0.59 | Beat 28.92% | — |
| Aug 14, 2025 | -$0.51 | -$1.00 | Miss -96.08% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026